Trial Information
A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724